{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:02:45Z","timestamp":1790085765346,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s12265-026-10846-9","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:22:54Z","timestamp":1790083374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mitochondrial Ferritin in Subclinical Anthracycline-Induced Cardiotoxicity in Humans: A Pilot Study"],"prefix":"10.1007","volume":"19","author":[{"given":"Giuseppe","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Santambrogio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Maria Rosa","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marchionni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Bucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Da Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pontara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Zambelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Margonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2022-774X","authenticated-orcid":false,"given":"Gabriele","family":"Fragasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"10846_CR1","doi-asserted-by":"publisher","first-page":"116362","DOI":"10.1016\/j.taap.2022.116362","volume":"459","author":"CE Bayles","year":"2023","unstructured":"Bayles CE, Hale DE, Konieczny A, Anderson VD, Richardson CR, Brown KV, et al. Upcycling the anthracyclines: new mechanisms of action, toxicology, and pharmacology. Toxicol Appl Pharmacol. 2023;459:116362. https:\/\/doi.org\/10.1016\/j.taap.2022.116362.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"10846_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","volume":"7","author":"M Volkova","year":"2011","unstructured":"Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214\u201320. https:\/\/doi.org\/10.2174\/157340311799960645.","journal-title":"Curr Cardiol Rev"},{"issue":"15","key":"10846_CR3","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","volume":"342","author":"GM Felker","year":"2000","unstructured":"Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077\u201384. https:\/\/doi.org\/10.1056\/NEJM200004133421502.","journal-title":"N Engl J Med"},{"issue":"1","key":"10846_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/heartjnl-2018-313234","volume":"105","author":"W Nadruz Jr","year":"2019","unstructured":"Nadruz W Jr, West E, Sengel\u00f8v M, Grove GL, Santos M, Groarke JD, et al. Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy. Heart. 2019;105(1):34\u201341. https:\/\/doi.org\/10.1136\/heartjnl-2018-313234.","journal-title":"Heart"},{"issue":"5","key":"10846_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","volume":"6","author":"M Camilli","year":"2024","unstructured":"Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM. Anthracycline cardiotoxicity in adult cancer patients: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2024;6(5):655\u201377. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.016.","journal-title":"JACC CardioOncol"},{"issue":"41","key":"10846_CR6","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J."},{"issue":"7","key":"10846_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/pbc.22637","volume":"55","author":"M Amigoni","year":"2010","unstructured":"Amigoni M, Giannattasio C, Fraschini D, Galbiati M, Capra AC, Madotto F, et al. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors. Pediatr Blood Cancer. 2010;55(7):1343\u20137. https:\/\/doi.org\/10.1002\/pbc.22637.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10846_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/pbc.25206","volume":"62","author":"K Leger","year":"2015","unstructured":"Leger K, Slone T, Lemler M, Leonard D, Cochran C, Bowman WP, et al. Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Pediatr Blood Cancer. 2015;62(1):123\u20137. https:\/\/doi.org\/10.1002\/pbc.25206.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10846_CR9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/pbc.22302","volume":"54","author":"M Rathe","year":"2010","unstructured":"Rathe M, Carlsen NL, Oxh\u00f8j H, Nielsen G. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg\/m2 or less for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54(3):444\u20138. https:\/\/doi.org\/10.1002\/pbc.22302.","journal-title":"Pediatr Blood Cancer"},{"issue":"36","key":"10846_CR10","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768\u2013801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211.","journal-title":"Eur Heart J."},{"key":"10846_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26. https:\/\/doi.org\/10.3389\/fcvm.2020.00026.","journal-title":"Front Cardiovasc Med"},{"key":"10846_CR12","doi-asserted-by":"publisher","first-page":"811406","DOI":"10.3389\/fphar.2022.811406","volume":"13","author":"J Huang","year":"2022","unstructured":"Huang J, Wu R, Chen L, Yang Z, Yan D, Li M. Understanding anthracycline cardiotoxicity from mitochondrial aspect. Front Pharmacol. 2022;13:811406. https:\/\/doi.org\/10.3389\/fphar.2022.811406.","journal-title":"Front Pharmacol"},{"key":"10846_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fphar.2014.00025","volume":"5","author":"E Gammella","year":"2014","unstructured":"Gammella E, Maccarinelli F, Buratti P, Recalcati S, Cairo G. The role of iron in anthracycline cardiotoxicity. Front Pharmacol. 2014;5:25. https:\/\/doi.org\/10.3389\/fphar.2014.00025.","journal-title":"Front Pharmacol"},{"issue":"7","key":"10846_CR14","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1073\/pnas.1821022116","volume":"116","author":"X Fang","year":"2019","unstructured":"Fang X, Wang H, Han D, Xie E, Yang X, Wei J, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci U S A. 2019;116(7):2672\u201380. https:\/\/doi.org\/10.1073\/pnas.1821022116.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10846_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","volume":"124","author":"Y Ichikawa","year":"2014","unstructured":"Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 2014;124(2):617\u201330. https:\/\/doi.org\/10.1172\/JCI72931.","journal-title":"J Clin Invest"},{"issue":"9","key":"10846_CR16","doi-asserted-by":"publisher","first-page":"e7095","DOI":"10.1371\/journal.pone.0007095","volume":"4","author":"D Cantu","year":"2009","unstructured":"Cantu D, Schaack J, Patel M. Oxidative inactivation of mitochondrial aconitase results in iron and H2O2-mediated neurotoxicity in rat primary mesencephalic cultures. PLoS ONE. 2009;4(9):e7095. https:\/\/doi.org\/10.1371\/journal.pone.0007095.","journal-title":"PLoS ONE"},{"issue":"3","key":"10846_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/s0022-2143(96)90095-5","volume":"127","author":"G Link","year":"1996","unstructured":"Link G, Tirosh R, Pinson A, Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med. 1996;127(3):272\u20138. https:\/\/doi.org\/10.1016\/s0022-2143(96)90095-5.","journal-title":"J Lab Clin Med"},{"issue":"25","key":"10846_CR18","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/j.jacc.2007.02.060","volume":"49","author":"GS Panjrath","year":"2007","unstructured":"Panjrath GS, Patel V, Valdiviezo CI, Narula N, Narula J, Jain D. Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol. 2007;49(25):2457\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2007.02.060.","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"10846_CR19","doi-asserted-by":"publisher","first-page":"24437","DOI":"10.1074\/jbc.C100141200","volume":"276","author":"S Levi","year":"2001","unstructured":"Levi S, Corsi B, Bosisio M, Invernizzi R, Volz A, Sanford D, et al. A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem. 2001;276(27):24437\u201340. https:\/\/doi.org\/10.1074\/jbc.C100141200.","journal-title":"J Biol Chem"},{"issue":"12","key":"10846_CR20","doi-asserted-by":"publisher","first-page":"6757","DOI":"10.1007\/s11033-013-2792-z","volume":"40","author":"E Cocco","year":"2013","unstructured":"Cocco E, Porrini V, Derosas M, Nardi V, Biasiotto G, Maccarinelli F, et al. Protective effect of mitochondrial ferritin on cytosolic iron dysregulation induced by doxorubicin in HeLa cells. Mol Biol Rep. 2013;40(12):6757\u201364. https:\/\/doi.org\/10.1007\/s11033-013-2792-z.","journal-title":"Mol Biol Rep"},{"issue":"8","key":"10846_CR21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00109-014-1147-0","volume":"92","author":"F Maccarinelli","year":"2014","unstructured":"Maccarinelli F, Gammella E, Asperti M, Regoni M, Biasiotto G, Turco E, et al. Mice lacking mitochondrial ferritin are more sensitive to doxorubicin-mediated cardiotoxicity. J Mol Med. 2014;92(8):859\u201369. https:\/\/doi.org\/10.1007\/s00109-014-1147-0.","journal-title":"J Mol Med"},{"issue":"25","key":"10846_CR22","doi-asserted-by":"publisher","first-page":"22430","DOI":"10.1074\/jbc.M105372200","volume":"277","author":"B Corsi","year":"2002","unstructured":"Corsi B, Cozzi A, Arosio P, Drysdale J, Santambrogio P, Campanella A, et al. Human mitochondrial ferritin expressed in HeLa cells incorporates iron and affects cellular iron metabolism. J Biol Chem. 2002;277(25):22430\u20137. https:\/\/doi.org\/10.1074\/jbc.M105372200.","journal-title":"J Biol Chem"},{"issue":"5","key":"10846_CR23","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood-2004-07-2722","volume":"105","author":"G Nie","year":"2005","unstructured":"Nie G, Sheftel AD, Kim SF, Ponka P. Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood. 2005;105(5):2161\u20137. https:\/\/doi.org\/10.1182\/blood-2004-07-2722.","journal-title":"Blood"},{"key":"10846_CR24","doi-asserted-by":"publisher","first-page":"33432","DOI":"10.1038\/srep33432","volume":"6","author":"M Guaraldo","year":"2016","unstructured":"Guaraldo M, Santambrogio P, Rovelli E, Di Savino A, Saglio G, Cittaro D, et al. Characterization of human mitochondrial ferritin promoter: identification of transcription factors and evidences of epigenetic control. Sci Rep. 2016;6:33432. https:\/\/doi.org\/10.1038\/srep33432.","journal-title":"Sci Rep"},{"issue":"5","key":"10846_CR25","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1182\/blood-2002-07-2006","volume":"101","author":"M Cazzola","year":"2003","unstructured":"Cazzola M, Invernizzi R, Bergamaschi G, Levi S, Corsi B, Travaglino E, et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood. 2003;101(5):1996\u20132000. https:\/\/doi.org\/10.1182\/blood-2002-07-2006.","journal-title":"Blood"},{"issue":"1","key":"10846_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/hmg\/ddn308","volume":"18","author":"A Campanella","year":"2009","unstructured":"Campanella A, Rovelli E, Santambrogio P, Cozzi A, Taroni F, Levi S. Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in Friedreich ataxia. Hum Mol Genet. 2009;18(1):1\u201311. https:\/\/doi.org\/10.1093\/hmg\/ddn308.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"10846_CR27","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1097\/NEN.0b013e3181bdc44f","volume":"68","author":"AM Snyder","year":"2009","unstructured":"Snyder AM, Wang X, Patton SM, Arosio P, Levi S, Earley CJ, et al. Mitochondrial ferritin in the substantia nigra in restless legs syndrome. J Neuropathol Exp Neurol. 2009;68(11):1193\u20139. https:\/\/doi.org\/10.1097\/NEN.0b013e3181bdc44f.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"7","key":"10846_CR28","doi-asserted-by":"publisher","first-page":"e22325","DOI":"10.1371\/journal.pone.0022325","volume":"6","author":"L Wang","year":"2011","unstructured":"Wang L, Yang H, Zhao S, Sato H, Konishi Y, Beach TG, et al. Expression and localization of mitochondrial ferritin mRNA in Alzheimer\u2019s disease cerebral cortex. PLoS ONE. 2011;6(7):e22325. https:\/\/doi.org\/10.1371\/journal.pone.0022325.","journal-title":"PLoS ONE"},{"issue":"8","key":"10846_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1161\/CIRCRESAHA.116.309202","volume":"119","author":"M Ackers-Johnson","year":"2016","unstructured":"Ackers-Johnson M, Li PY, Holmes AP, O\u2019Brien SM, Pavlovic D, Foo RS. A simplified, langendorff-free method for concomitant isolation of viable cardiac myocytes and nonmyocytes from the adult mouse heart. Circ Res. 2016;119(8):909\u201320. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.309202.","journal-title":"Circ Res"},{"issue":"3","key":"10846_CR30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","volume":"13","author":"K Ananthan","year":"2020","unstructured":"Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. J Cardiovasc Transl Res. 2020;13(3):431\u201350. https:\/\/doi.org\/10.1007\/s12265-020-10042-3.","journal-title":"J Cardiovasc Transl Res"},{"issue":"6","key":"10846_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/heartjnl-2015-307894","volume":"102","author":"AF Yu","year":"2016","unstructured":"Yu AF, Ky B. Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart. 2016;102(6):425\u201330. https:\/\/doi.org\/10.1136\/heartjnl-2015-307894.","journal-title":"Heart"},{"issue":"1","key":"10846_CR32","doi-asserted-by":"publisher","first-page":"11425","DOI":"10.1038\/s41598-020-68205-w","volume":"10","author":"F Andreata","year":"2020","unstructured":"Andreata F, Bonizzi A, Sevieri M, Truffi M, Monieri M, Sitia L, et al. Co-administration of H-ferritin-doxorubicin and trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2\u2009+\u2009murine breast cancer model. Sci Rep. 2020;10(1):11425. https:\/\/doi.org\/10.1038\/s41598-020-68205-w.","journal-title":"Sci Rep"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10846-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-026-10846-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10846-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:22:55Z","timestamp":1790083375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-026-10846-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10846"],"URL":"https:\/\/doi.org\/10.1007\/s12265-026-10846-9","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing conflicts of interest.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study. All data are collected and processed anonymously.","order":3,"name":"Ethics","label":"Human Subjects\/Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed and approved by the appropriate institutional committees.","order":4,"name":"Ethics","label":"Animal Studies","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"These results provide preliminary evidence supporting further investigation of mitochondrial ferritin in the setting of anthracycline exposure, where it may contribute to a better understanding of the mechanisms underlying early myocardial injury and its potential role in future biomarker-based risk stratification.","order":6,"name":"Ethics","label":"Clinical Relevance","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"118"}}